- World Pharma News Home » Product » FDA Issues Approvable Letter for Nebivolol for the Treatment of Hypertension
(a free service delivered by FeedBurner)
Forest Laboratories, Inc. (NYSE: FRX) and Mylan Inc. (NYSE: MYL) announced that Mylan has received an approvable letter from the U.S. Food and Drug Administration (FDA) in response to its New Drug Application (NDA) for nebivolol (proposed brand name Bystolic(TM)), a novel beta blocker under review for the treatment of hypertension.
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Comments